SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing polarized discussion as some traders anticipate institutional adoption and ecosystem expansion through the integration of Chain's technology and new debit card functionality, while others dismiss the price action as a recurring pump-and-dump scheme. Skepticism remains high among critics who point to the project's long-term price decline, lack of confirmed commercial partnerships, and frustration with official communication.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

The conversation surrounding Hedera is highly fragmented and generally pessimistic, with many traders expressing frustration over the token's persistent decline and labeling it a "scam" due to its significant pullback from historical highs. While some long-term holders remain bullish, citing institutional partnerships, tokenized real-world asset growth, and expectations for the "Clarity Act" to provide regulatory certainty, others are actively shorting the asset or waiting for lower entry points near the five-to-six cent range.

Lockheed Martin Corp. is a global security and aerospace company, which engages in the research, design, development, manufacture, integration, and sustainment of technology systems, products, and services. It operates through the following business segments: Aeronautics, Missiles and Fire Control (MFC), Rotary and Mission Systems (RMS), and Space. The Aeronautics segment researches, designs, develops, manufactures, integrates, sustains, supports, and upgrades advanced military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. The MFC segment is involved in air and missile defense systems, tactical missiles and air-to-ground precision strike weapon systems, logistics, fire control systems, mission operations support, readiness, engineering support and integration services, manned and unmanned ground vehicles, and energy management solutions. The RMS segment designs, manufactures, services, and supports various military and commercial helicopters, surface ships, sea and land-based missile defense systems, radar systems, sea and air-based mission and combat systems, command and control mission solutions, cyber solutions, and simulation and training solutions. The Space segment includes the production of satellites, space transportation systems, and strategic, advanced strike, and defensive systems. The company was founded in 1995 and is headquartered in Bethesda, MD.

Lockheed Martin Corp.

Lockheed Martin is trending following a record-breaking second-quarter earnings report, where a significant increase in backlog orders and raised full-year guidance fueled investor optimism. While the broader defense sector continues to see strong demand driven by government contract wins and geopolitical tensions, some traders remain cautious about the stock's recent volatility and valuation.

Frequency Electronics, Inc. engages in the design, development, and manufacture of precision time and frequency generation technology. It operates through the following business segments: FEI-NY and FEI-Zyfer. The FEI-NY segment provides precision time, frequency generation, and synchronization products and subsystems that are found on-board satellites, in ground-based communication stations, and imbedded in moving platforms. The FEI-Zyfer segment designs, develops, and manufactures products for precision time and frequency generation and synchronization, primarily incorporating GPS technology. The company was founded by Martin B. Bloch on August 25, 1961 and is headquartered in Uniondale, NY.

Frequency Electronics, Inc.

Frequency Electronics is trending following strong momentum fueled by investor focus on its critical role in quantum sensing and space-based defense technologies. Traders are highlighting the company's substantial funded backlog and its involvement in next-generation aerospace initiatives, such as the Golden Dome program, as key catalysts for potential long-term growth.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending due to community discussion regarding its robust HIV franchise growth, ongoing expansion of its oncology pipeline, and speculative interest in potential strategic acquisitions to bolster long-term value.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

Subsquid is receiving attention as traders debate the long-term potential of its decentralized data indexing infrastructure and its integration with Rezolve AI. While many investors express a bullish outlook regarding enterprise adoption and real-world data utility, others are more skeptical, viewing the token's recent price action with caution or skepticism regarding management's transparency.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending following a failed late-stage clinical trial for its breast cancer drug Etcamah, which missed its primary endpoint of improving progression-free survival. While some traders view the resulting price decline as a buying opportunity, others are expressing concern over the recent string of trial setbacks impacting the company's pipeline.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson shares are trending as investors monitor potential developments regarding the separation of its orthopedics business, with reports indicating interest from private-equity firms like Apollo Global Management in a deal valued at approximately $20 billion. Despite the potential for a sale or spin-off, some retail sentiment remains bearish while discussion centers on the company's strategic focus on other therapeutic areas.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo shares are facing downward pressure following the announcement of a new $1 billion at-the-market equity offering program, which has reignited concerns among traders regarding shareholder dilution. While some investors remain bullish on the long-term potential of the company's advanced nuclear reactor technology and its role in meeting data center energy demand, others are frustrated by the consistent selling activity and the company's lack of commercial revenue.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending as investors react to the company's recent FDA approval of Revtorpyk, while monitoring commercial launch progress and anticipation for the upcoming sNDA submission for the PIK3CA-mutant patient population. Despite the approval, discussions remain active regarding the stock's valuation, launch timeline expectations, and potential for acquisition by Big Pharma.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$WDS Great earnings here.

Australia&#39;s real GDP grew by 0.4% in the June quarter of 2026, bringing the annual growth rate to 2.1% through the year to June.Key June 2026 Quarter StatisticsQuarterly Growth (QoQ): Up 0.4% in seasonally adjusted chain volume measures.Annual Growth (YoY): Up 2.1% compared to the June quarter of 2025, beating market forecasts of 1.8%.Nominal GDP Quarterly Change: Rose 0.8%.GDP Per Capita: Flat (0.0%) for the quarter and up 0.7% over the year, indicating overall growth was largely driven by population increases.Household Saving Ratio: Increased to 6.5%, up from 6.4% in the previous period

David

Mirjam

StockTwits for iOS

Woodside Energy Group Ltd - ADR

 Great earnings here.

Australia's real GDP grew by 0.4% in the June quarter of 2026, bringing the annual growth rate to 2.1% through the year to June.Key June 2026 Quarter StatisticsQuarterly Growth (QoQ): Up 0.4% in seasonally adjusted chain volume measures.Annual Growth (YoY): Up 2.1% compared to the June quarter of 2025, beating market forecasts of 1.8%.Nominal GDP Quarterly Change: Rose 0.8%.GDP Per Capita: Flat (0.0%) for the quarter and up 0.7% over the year, indicating overall growth was largely driven by population increases.Household Saving Ratio: Increased to 6.5%, up from 6.4% in the previous period